<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637286</url>
  </required_header>
  <id_info>
    <org_study_id>D1223C00002</org_study_id>
    <nct_id>NCT00637286</nct_id>
  </id_info>
  <brief_title>ZAP, US. Zomig for Appropriate for Primary Care</brief_title>
  <official_title>A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™
      (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in
      treating migraine over a period of 6 months
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Migraine Disability Assessment questionnaire (MIDAS) score</measure>
    <time_frame>Twice within 28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore patients assessment of value of zolmitriptan</measure>
    <time_frame>Maximum of 3 times between 1 - 28 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">120</enrollment>
  <condition>Migraine</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolmitriptan</intervention_name>
    <description>5mg Nasal Spray</description>
    <other_name>Zomig</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have an established diagnose of migraine as with an age at onset of less than 50 years

          -  Have experienced an average of at least 1 migraine headache per month in the previous
             three months

          -  Be able to differentiate between migraine and non-migraine headaches

        Exclusion Criteria:

          -  Use of any triptan within the last 12 months or use of MAO-A inhibitors, methysergide
             or methylergonovine in the 2 weeks before entering the study.

          -  History of basilar, ophthalmoplegic or hemiplegic migraine headache or any potentially
             serious neurological condition that is associated with headache

          -  History, symptoms, or significant risk factors for ischaemic heart or other
             cardiovascular disease, including coronary vasospasm, cardiac accessory conduction
             pathways or arrhythmias or uncontrolled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2008</study_first_posted>
  <last_update_submitted>April 3, 2009</last_update_submitted>
  <last_update_submitted_qc>April 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2009</last_update_posted>
  <keyword>Zolmitriptan</keyword>
  <keyword>ZOMIG</keyword>
  <keyword>migraine</keyword>
  <keyword>headache response</keyword>
  <keyword>headache</keyword>
  <keyword>headache pain</keyword>
  <keyword>MIDAS</keyword>
  <keyword>HCPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

